Trial Profile
A Phase III, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When Administered in Combination With the Abacavir/Lamivudine Fixed-Dose Combination Tablet as a Once-Daily Regimen in Antiretroviral-Naive HIV-1 Infected Subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Aug 2023
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Lamivudine/abacavir (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- Sponsors GSK
- 11 Oct 2005 New trial record.